United States has identified sources of specific raw material urgently required for Indian manufacture of Covishield vaccine that will immediately be made available for India. US National Security Advisor Jake Sullivan spoke by phone today with National Security Advisor Ajit Doval, expressing "deep sympathy" for the people of India following the recent spike in COVID19 cases.
US has identified supplies of therapeutics, rapid diagnostic test kits, ventilators & PPE that will immediately be made available for India. US is also pursuing options to provide oxygen generation & related supplies on an urgent basis: US NSA Jake Sullivan to NSA Ajit Doval
US Development Finance Corporation (DFC) is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India, enabling BioE to ramp up to produce at least 1 billion COVID19 doses of vaccines by end of 2022: US NSA Sullivan to NSA Doval
United States is also deploying an expert team of public health advisors from Center for Disease Control (CDC) & USAID to work in close collaboration with US Embassy, India’s health ministries & its Epidemic Intelligence Service staff: US NSA Jake Sullivan to NSA Ajit Doval
Statement by NSC Spokesperson Emily Horne on National Security Advisor Jake Sullivan's Call with National Security Advisor Ajit Doval of India
National Security Advisor Jake Sullivan spoke by phone today with National Security Advisor Ajit Doval, expressing deep sympathy for the people of India following the recent spike in COVID-19 cases. Mr. Sullivan affirmed America's solidarity with India, the two countries with the greatest number of COVID-19 cases in the world. Building on the sevendecade health partnership between the United States and India -including battles against smallpox, polio, and HIV — they resolved that India and the United States will continue to fight the global COVID-19 pandemic together. Just as India sent assistance to the United States as our hospitals were strained early in the pandemic, the United States is determined to help India in its time of need.
To this end, the United States is working around the clock to deploy available resources and supplies. The United States has identified sources of specific raw material urgently required for Indian manufacture of the Covishield vaccine that will immediately be made available for India. To help treat COVID-19 patients and protect front-line health workers in India, the United States has identified supplies of therapeutics, rapid diagnostic test kits, ventilators, and Personal Protective Equipment (PPE) that will immediately be made available for India.
The United States also is pursuing options to provide oxygen generation and related supplies on an urgent basis. The U.S. Development Finance Corporation (DFC) is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India, enabling BioE to ramp up to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022. Additionally, the United States is deploying an expert team of public health advisors from the Center for Disease Control (CDC) and USAID to work in close collaboration with the U.S. Embassy, India's health ministries, and India's Epidemic Intelligence Service staff. USAID will also quickly work with CDC to support and fast-track the mobilization of emergency resources available to India through the Global Fund.
The two National Security Advisors agreed that the U.S. and India would stay in close touch in coming days.
